Kelun Pharmaceutical Holdings subsidiary SKB378/HBM9378 injection obtained clinical trial notice

On February 21, Kelun Pharmaceutical issued an announcement saying that the SKB378/HBM9378 injection jointly developed by its holding subsidiary Kelun Botai and Hebo Pharmaceutical obtained the clinical trial notice from the State Drug Administration, agreeing to carry out moderate-to-severe clinical trials for this product.
Clinical trials in asthma indications
.

SKB378/HBM9378 injection is a class 1 innovative drug with global intellectual property rights jointly developed by Sichuan Kelun Botai Biopharmaceutical Co.
, Ltd.
and Hebo Pharmaceutical using the Hebo medical technology platform H2L2 fully human mouse, targeting TSLP (thymic stromal lymphopoietin, a fully human monoclonal antibody against thymic stromal lymphopoietin), the two parties confirmed that Sichuan Kelun Botai Biopharmaceutical Co.
, Ltd.
and Hebo Pharmaceutical (Shanghai) Co.
, Ltd.
will be the sponsors to promote clinical research
.

As of now, AstraZeneca/Amgen's Tezepelumab is the world's most advanced monoclonal antibody with the same target, which was approved for marketing in the United States on December 17, 2021, and is undergoing Phase III clinical trials in China test
.